France's Exosens rises to near seven-month high on fresh guidance
08/01/2025 10:09
** Shares of aerospace and defence manufacturer Exosens
EXENS.PA rise as much as 10.2% to its highest since mid-June,
after it presents its estimated 2024 financial results and 2025
outlook
** The firm expects its 2024 results to exceed guidance set
during IPO; sees total revenue range of 390 mln-395 mln euros,
and adjusted core profit of between 116 mln-118 mln euros
** Exosens also expects adjusted EBITDA to grow in 2025 by
low twenties-percent compared with 2024
** ODDO BHF analyst Aurelien Sivignon says the "main reason"
behind the promising guidance is the German parliament's
approval of third option of the OCCAR night vision contract in
mid-December
** Based on that, Exosens sees 2024-2026 adjusted EBITDA
CAGR (compound annual growth rate) in high-teens percentage
range and a cash conversion ratio of 75%-80%
** Stock is up 10.1% at 1005 GMT, outperforming France's
blue-chip index CAC40 .FCHI
(Reporting by Mateusz Rabiega)
((Mateusz.rabiega@thomsonreuters.com;))